# AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

> **NCT01018069** · PHASE2 · TERMINATED · sponsor: **Aegera Therapeutics** · enrollment: 60 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** AEG35156

## Key facts

- **NCT ID:** NCT01018069
- **Lead sponsor:** Aegera Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 60 (ESTIMATED)
- **Why stopped:** Failed to reach endpoints
- **Last updated:** 2011-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01018069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01018069, "AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01018069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*